Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin
Study will provide additional metabolic data on ORMD-0801 in patients with type 1 diabetes NEW YORK, June 25, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in its Glucose Clamp Study […]
